Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit
18 mai 2021 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021
11 mars 2021 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit...
Revolution Medicines to Participate in Upcoming Investor Conferences
09 mars 2021 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences
18 févr. 2021 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
Global Bed Head Panel Market – Analysis and Demand with Forecast Overview to 2029 - by PMI
19 janv. 2021 22h05 HE
|
PMI
Covina CA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- The global bed head panel market for US$ 2.0 billion in 2019 is anticipated to register a CAGR of 5.5%. The report " Global Bed Head Panel Market, By...
Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress
12 nov. 2020 07h30 HE
|
Revolution Medicines, Inc.
Recommended Phase 2 Dose and Schedule Selected for Further Evaluation of RMC-4630 as Monotherapy and RMC-4630 plus Cobimetinib Combination First-in-Class RAS(ON) Inhibitor Programs for Five Targets...
Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
18 févr. 2020 16h01 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive...
Receptor Holdings Adds Alex Casdin to Board of Directors
08 avr. 2019 08h50 HE
|
Receptor Holding
SEATTLE, April 08, 2019 (GLOBE NEWSWIRE) -- Alexander W. Casdin, Founder, CEO, and Portfolio Manager of Reneo Capital Management LP, has been named to the Board of Directors of Receptor Holdings...
Precision Medicine Market USD 88.64 Billion Revenue Witnesses High Demand due to Prevalence of Genetic Diseases Forecasts by 2022
04 sept. 2018 11h02 HE
|
Market Research Future
Pune, India, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Market Research Future has released its report on the Global Precision Medicine Market which projects above-average growth and various market...
Yamaha FAZER Remotely Piloted Helicopter Receives FAA Approval
26 juin 2018 09h00 HE
|
Yamaha Motor Corp., USA
CYPRESS, Calif., June 26, 2018 (GLOBE NEWSWIRE) -- Yamaha Motor Corp., USA, has received an exemption from the Federal Aviation Administration (FAA) to begin using its FAZER remotely piloted...